---
input_text: 'Allogeneic Hematopoietic Stem Cell Transplant Offer Good Outcomes in
  Pediatric Aplastic Anemia: Experience From Developing World. Between 2014 and 2020,
  31 patients with severe aplastic anemia (SAA) underwent full match allogeneic hematopoietic
  stem cell transplantation at our center. Of the 31 patients with SAA, 19 had acquired
  aplastic anemia, 2 had Diamond Blackfan anemia and 10 had Fanconi anemia. Donors
  were either matched sibling (n=29), related donors (n=2), or unrelated donors (n=3).
  Peripheral blood stem cells were the graft source in all the cases except 1. Fludarabine-based
  reduced intensity conditioning was used in all except for patients with a diagnosis
  of Diamond Blackfan anemia. All patients except 1 achieved hematologic recovery
  in the form of neutrophil engraftment at 13 days (range, 9 to 17), whereas platelet
  engraftment occurred at 14 days (range, 10 to 18). Graft versus host disease (GvHD)
  prophylaxis consisted of cyclosporine and methotrexate +-antithymocyte globulin
  (horse/rabbit). Acute GvHD developed in 12.9% patients, whereas no patients developed
  chronic GvHD till the time of last follow-up. The 2-year overall survival for the
  entire cohort was 93.21+-4.6%. In patients with SAA, allogeneic stem cell transplant
  using fludarabine-based conditioning regimens are very well tolerated and have excellent
  outcomes in a full match setting.'
raw_completion_output: |-
  primary_disease: aplastic anemia

  medical_actions: allogeneic hematopoietic stem cell transplantation; fludarabine-based reduced intensity conditioning; graft versus host disease (GvHD) prophylaxis with cyclosporine and methotrexate +-antithymocyte globulin (horse/rabbit)

  symptoms: severe aplastic anemia; acute GvHD

  chemicals: cyclosporine; methotrexate; fludarabine; antithymocyte globulin

  action_annotation_relationships: allogeneic hematopoietic stem cell transplantation TREATS severe aplastic anemia IN aplastic anemia; fludarabine-based reduced intensity conditioning PREVENTS acute GvHD IN aplastic anemia; graft versus host disease (GvHD) prophylaxis with cyclosporine (with methotrexate and antithymocyte globulin) PREVENTS acute GvHD IN aplastic anemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  graft versus host disease (GvHD) prophylaxis with cyclosporine (with methotrexate and antithymocyte globulin) PREVENTS acute GvHD IN aplastic anemia

  ===

extracted_object:
  primary_disease: MONDO:0015909
  medical_actions:
    - MAXO:0001479
    - fludarabine-based reduced intensity conditioning
    - graft versus host disease (GvHD) prophylaxis with cyclosporine and methotrexate
      +-antithymocyte globulin (horse/rabbit)
  symptoms:
    - severe aplastic anemia
    - acute GvHD
  chemicals:
    - CHEBI:4031
    - CHEBI:44185
    - fludarabine
    - antithymocyte globulin
  action_annotation_relationships:
    - subject: <transplantation>
      predicate: <TREATS>
      object: <aplastic anemia>
      qualifier: <aplastic anemia>
      subject_qualifier: <>
      object_qualifier: <severe>
      subject_extension: <allogeneic hematopoietic stem cell>
      object_extension: <severe>
    - subject: reduced intensity conditioning
      predicate: PREVENTS
      object: GvHD
      qualifier: MONDO:0015909
      subject_qualifier: fludarabine-based
      object_qualifier: acute
      subject_extension: fludarabine
      object_extension: acute
    - subject: graft versus host disease (GvHD) prophylaxis
      predicate: PREVENTS
      object: GvHD
      qualifier: MONDO:0015909
      subject_qualifier: with methotrexate and antithymocyte globulin
      object_qualifier: acute
      subject_extension: CHEBI:4031
      object_extension: acute
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
